Moving beyond the restricted expression of CD19 on the B cell lineage and nearly uniform expression on B cell malignancies, identifying ubiquitously expressed tumor-associated antigens in solid tumors with limited ‘on-target/off-tumor’ risk has proved complicated. This evidence concerns the gene CD19 and neoplasm.